When to Test Your IGF-1 on Peptides: Draw Timing, Fasting Rules, and Result Interpretation

The morning fasting rule everyone follows before an IGF-1 blood test is half right for the wrong reason. IGF-1 does not meaningfully change with food intake. What moves is growth hormone, and nobody is drawing GH. Yet three of the most common timing mistakes people make when testing IGF-1 on a peptide protocol all trace back to this one misunderstanding about what the test is actually measuring.

Total IGF-1 -- the form measured by every standard clinical lab -- has a half-life of 15 to 20 hours when bound to its carrier protein IGFBP-3. It does not spike and crash like GH. It reflects cumulative GH exposure over days, not the last pulse. That is exactly why the AACE's acromegaly monitoring guidelines specify a "random serum IGF-1": no timed draw window required. You can test at 8 AM or 2 PM and get nearly identical numbers.

The problem is not time of day. The problem is which week of your protocol you test, which compound you are on, and whether you took a biotin supplement in the past three days. Get those three things wrong and you can misread your protocol entirely -- either dose-correcting a number that was never real, or missing an elevation that should have prompted a cycle break.

The Three Draw Rules That Determine Whether Your IGF-1 Number Is Actually Accurate

Every IGF-1 timing error on a peptide protocol comes back to one of these three rules. All three must be satisfied before the result means anything.

Rule 1: Draw at trough, before your day's first dose

Morning before your injection is the universal trough-time standard. For pulsatile stacks (ipamorelin, Mod GRF 1-29, sermorelin dosed multiple times daily), the morning before your first dose is when circulating peptide is lowest. This is the most reproducible moment in your dosing cycle, and it is the time point that clinical monitoring protocols use for consistency. Drawing two hours after an injection does not dramatically change total IGF-1 (the acute GH spike does not translate to IGF-1 within a few hours), but it adds unnecessary noise to a measurement you want to be as stable as possible.

For CJC-1295 with DAC on a once-weekly schedule, the trough concept changes. A single injection can keep IGF-1 elevated for 9 to 11 days, according to the 2006 Phase 1/2 trial by Teichman et al. in the Journal of Clinical Endocrinology and Metabolism. On weekly dosing, your IGF-1 is elevated throughout the entire dosing interval. The practical convention: draw mid-week, 4 to 5 days after your injection, to capture the plateau rather than the acute peak.

Rule 2: Draw after steady state, not at week one

This is the mistake most people make. IGF-1 does not jump the moment you start a protocol. It rises gradually as the liver accumulates GH signal over days and weeks. Testing at week one gives you a number that is probably still climbing. It tells you almost nothing about where your protocol will plateau.

For daily pulsatile stacks (ipamorelin with Mod GRF), steady state typically establishes by weeks 3 to 4. That is when a trough draw is actually informative. For MK-677 at 25 mg daily, the Chapman et al. 1996 JCEM trial showed IGF-1 elevation plateauing by weeks 4 to 6 of continuous use. The Nass et al. two-year RCT confirmed that elevation stayed 60% above baseline for all 24 months, which means the plateau is durable once established. Test no earlier than week 4 on MK-677, and ideally week 6 if you want the most stable baseline. See the tesamorelin vs MK-677 vs CJC-1295 comparison for context on how each compound's evidence base differs.

Rule 3: Stop biotin at least 72 hours before your draw

This is the rule almost no one follows, and it is responsible for a surprising share of "weird" IGF-1 results. Biotin (vitamin B7) is the active ingredient in most hair, nail, and skin supplements. Many multivitamins contain 300 to 10,000 mcg per serving. Clinical IGF-1 assays on platforms such as Siemens Immulite and DiaSorin use streptavidin-biotin coupling as part of the immunoassay detection chemistry. Excess circulating biotin competes with the assay's own biotinylated components, pushing the result either falsely high or falsely low depending on assay format.

The FDA issued a specific safety communication in November 2017 warning that high-dose biotin was causing false results across a range of hormone immunoassays, including some that had led to missed diagnoses and incorrect dosing decisions. The standard recommendation across lab medicine: stop biotin for at least 48 to 72 hours before any immunoassay-based hormone panel. If you take a high-dose biotin supplement (1000 mcg or more per day), stop for 72 hours minimum.

Should You Fast Before an IGF-1 Blood Test? The Real Answer

Yes. But the reason most people are given is wrong.

The instruction "fast for 8-12 hours before your IGF-1 test" implies that food raises or lowers IGF-1. It does not, at least not from a single meal or overnight window. A 2022 randomized crossover study by Hollstein et al. in the Journal of Clinical Endocrinology and Metabolism specifically tested this. After a complete 24-hour fast, total IGF-1 changed by an average of -1.73 ng/mL, which was not statistically significant. GH spiked approximately 5-fold in the same window. IGF-1 stayed essentially flat.

"Total IGF-1 concentrations did not change significantly during 36 hours of complete caloric restriction in healthy adults, despite a roughly 5-fold increase in circulating growth hormone over the same period."

Hollstein T et al., Journal of Clinical Endocrinology and Metabolism, 2022

So why fast? Because your IGF-1 test is almost never drawn alone. It comes with a co-panel: fasting glucose, fasting insulin, lipid panel, and sometimes hsCRP. Those tests absolutely require an overnight fast. The IGF-1 is riding along on a panel that needs the fasting state. Fast because of what you are testing alongside the IGF-1, not because the IGF-1 itself needs it.

There is one real exception. Prolonged caloric restriction (multi-day fasting or a sustained aggressive deficit) does suppress total IGF-1. A 2002 JCEM study by Katz et al. showed approximately a 34% drop in total IGF-1 during prolonged fasting, driven by an 11-fold rise in IGFBP-1 that sequestered more IGF-1 away from measurement. If you are in a heavy caloric deficit at test time, your IGF-1 will read lower than your actual protocol level. Test during a normal-feeding period, not during a fat-loss phase cut.

When to Draw By Compound: The Timing Cheat Sheet

The right draw timing varies significantly by peptide. Pulsatile daily stacks, long-acting GHRH analogs, and oral secretagogues each have a different steady-state pharmacology. Here is the compound-by-compound guide.

For a deeper look at how the evidence base differs between these compounds, the tesamorelin vs MK-677 vs CJC-1295 article covers every RCT that actually exists for each. The short version: tesamorelin has Phase III data, MK-677 has two years of human trial data, and CJC-1295 has never completed a body composition RCT.

How to Read Your IGF-1 Result: Age-Adjusted Ranges and What the Number Actually Means

The single most common misreading of IGF-1 results is ignoring age. A result of 220 ng/mL looks low-normal at 28 and high-normal at 65. Both readings are correct within their age group, and they represent completely different situations. Always use age-and-sex-adjusted reference ranges from your lab, not a flat target number.

Reference ranges are from a 2021 population study (Stojanovic et al., Acta Endocrinologica, PMC9206165) on 422 healthy adults. Apply them as approximate guidance, not absolute limits. Your lab's specific assay may produce different absolute numbers even from the same blood sample: Roche Cobas and Siemens Immulite platforms have documented calibration differences. For longitudinal monitoring, use the same lab and the same assay every time. Never compare a raw number from LabCorp against a previous result from Quest.

Goal-stratified targets vary by protocol objective. Anti-aging longevity-focused users typically aim to restore IGF-1 to the mid-normal range for their age, not to the top of the range or above it. Performance-focused users often target the upper quartile of their age-matched range. Users optimizing specifically for tissue repair (tendons, post-surgical healing) follow the same principle. The research does not clearly support targeting IGF-1 above the age-matched upper normal for general health outcomes, and some longevity data points in the opposite direction.

Your IGF-1 Result Came Back Off. Here Is What to Check First.

Before adjusting your protocol, rule out these four confounders in order. Most "unexpected" IGF-1 results trace back to one of them.

The question of how quickly IGF-1 responds to a dose change is one most protocols ignore. After a dose reduction, expect IGF-1 to begin declining within a week and reach a new stable level in 2 to 3 weeks. After a dose increase, give 3 to 4 weeks before retesting. Testing too soon after any dose adjustment gives you a transitional number, not a steady-state number, and it leads to over-correction.

How GHR Exon 3 Status Changes Your Target Range

Your GHR genotype changes how much IGF-1 your cells generate per unit of GH signal, which means the same protocol produces meaningfully different IGF-1 readings depending on your genetics. This is not a minor detail. A 2004 Nature Genetics study (Dos Santos et al.) showed that d3 allele carriers run a more efficient GH receptor configuration, generating up to 56% more downstream IGF-1 response per GH pulse under some conditions. About half the population carries at least one d3 allele. Roughly 10 to 20% are d3/d3 homozygous.

For d3/d3 carriers, the practical implication is that standard MK-677 or CJC-1295 doses can push IGF-1 to the top of the age-adjusted range, or above it, without producing obvious symptoms. The GHR Exon 3 deletion article covers the receptor mechanics in detail. The short version: d3/d3 carriers should retest at week 4 rather than waiting for week 8 or 12, and their target IGF-1 range may be lower in absolute terms than the community-standard "250-350 ng/mL" guidelines suggest for their age group.

The IGFBP-3 layer adds another dimension. About 75 to 80% of circulating IGF-1 is bound in a large ternary complex with IGFBP-3 and ALS. Carriers of IGFBP-3 rs2854744 variants that reduce IGFBP-3 production have more free IGF-1 circulating at the same total IGF-1 number. Their labs can look "normal" while their actual bioavailable IGF-1 exposure is elevated. Running both IGF-1 and IGFBP-3 at the same draw -- and looking at the ratio -- gives a more complete picture than either marker alone. A 2023 JCEM study (Haj-Ahmad et al.) found that the IGF-1/IGFBP-3 molar ratio tracked GH activity more accurately than total IGF-1 in clinical populations. For the detailed genetics interpretation, the IGF-1 receptor genetics guide covers IGFBP-3 and the full genetic picture.

Your genetics do not change when to test. They change how to interpret the number once you have it. Get the timing right first. Layer the genetics interpretation after.

If you want to know your actual GHR and IGFBP-3 status, your genetic report for ipamorelin includes both variants alongside the full panel of receptor and metabolizer genes that determine your GH peptide response. It is the fastest way to move from a confusing IGF-1 result to a clear protocol decision.